MedPath
NMPA Approval

Pasireotide Pamoate Microspheres for Injection

国药准字HJ20250048

April 22, 2025

Drug Information

注射用双羟萘酸帕瑞肽微球

注射剂

20mg(按C₅₈H₆₆N₁₀O₉计)

化学药品

April 22, 2025

April 21, 2030

Company Information

Applicant Company

Tour Hekla, 52 avenue du Général de Gaulle, 92800 Puteaux, France

Manufacturing Company

recordati ag rare diseases branch(生产注射用粉末半成品);novartis pharmaceutical manufacturing gmbh(制剂的初级包装);synergy health däniken ag(灭菌)

Lichtstrasse 35, 4056 Basel, Switzerland(生产注射用粉末半成品);Biochemiestrasse 10, 6336 Langkampfen Austria(制剂的初级包装);Hogenweidstrasse 6, 4658 Däniken Switzerland(灭菌)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

注射用双羟萘酸帕瑞肽微球 - NMPA 批准文号 | MedPath